Clinical Trials Directory

Trials / Unknown

UnknownNCT05591742

Bacterial Composition and Recurrent Cystitis in Postmenopausal Women After Treatment With Lactobacilli.

The Effect on Bacterial Composition in Urine, Vagina and Faces After Treatment With Lactobacilli and Its Influence on Recurrent Cystitis in Postmenopausal Women.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Aalborg University Hospital · Academic / Other
Sex
Female
Age
50 Years
Healthy volunteers
Accepted

Summary

The goal of this clinical trial is to learn about the effect on the bacterial composition in the microbiome (the body's own bacteria) of urine, vagina and faeces after treatment with lactobacilli (lactobacilli's are a part of the microbiome), and its influence on repeated cystitis in postmenopausal women. The main questions it aims to answer are: * Does treatment with lactobacilli change the composition of the urine microbiome in postmenopausal women? * Does treatment with lactobacilli prevent repeated cystitis in postmenopausal women? Participants will be followed for 6 months. They will for 3 months receive a look-alike substance that contains no active drug and for the other 3 months tablets with lactobacilli. A computer program will decide what treatment the participant will begin with, and after 3 months she will be receiving the tablets, she did not get first. This way all participants receive both type of tablets and can be their own control. What type of tablet the participants is taking is unknown to both clinical staff and participants. The participants will come to the hospital for start-up, and every 1,5 moths for the next 6 months. They deliver * faeces sample * urine tests * vaginal swab each time they are seen. When entering the study, they also complete health care questions on medication, earlier surgery, alcohol, tobacco, childbirths, weight, height etc. They make a drinking and voiding diary 3 times over the 6 months. When the study is over, alle the samples of faeces, urine and the vaginal swab will undergo analyzation for the bacterial composition in the microbiome, and differences in the microbiome when taking lactobacilli or not will be examined. The urine sample is controlled for bacteria known to give cystitis, and the influence on repeated cystitis will also be examined.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTFEMIDUR®Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day. Placebo Z Cap V-3 Pla; mainly maltodextrin
OTHERPlacebo Z Cap V-3 PlaConsist mainly of maltodextrin. One tablet a day.

Timeline

Start date
2021-10-01
Primary completion
2024-10-01
Completion
2025-10-01
First posted
2022-10-24
Last updated
2024-02-05

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05591742. Inclusion in this directory is not an endorsement.